

## AGENDA

Date 3/3/16

### Attendees:

Chris Stoeckert  
Heather Williams  
Jihad Obeid  
Mathias Brochhausen  
Helena Ellis  
Jie Zheng  
David Birtwell  
Frank Manion  
He Y.

### Not today:

### Notes:

- Agenda based on last meeting notes:
  - identify use cases to model: take one or two from the grant. Grant has four use cases:
    - 1) Identify cases and controls from a population of patients that have EDTA blood or DNA specimen available ***who have consented to be recontacted for future research study request (broad biobank consent)***
      - ***Duke's language "Future Contact: Duke Researchers who are studying your materials may want to contact you if they need more information that is important for their research. Researchers will only be allowed to contact you if their study is approved by the Duke Institutional Review Board and if you indicate 'yes' below."***
    - 2) "Identify large or small, normal tissue, intestine samples –from the Pathology paraffin archives, from patients with Parkinson's disease who ***have consented to a Broad Consent protocol*** (e.g., one from Duke that allows access to retrospective as well as prospective excess tissue)."
    - 3) "and who ***do*** have a plasma sample in the Biorepository that ***has been consented for allowable use of specimens.***"
    - 4) "***Identify specimens available for research use for researchers engaged in a patient centered outcomes research network***"
  - Review gaps in ICO using webprotege (e.g. what we said in the grant)
  - do the types support the competency questions
  - Discussed Process of development:
    - Ontology developers draft ontology model
    - Then Bring back to this call to make sure we captured the domain and there is agreement with the model.

- Jie posted ICO paper link:  
[http://ceur-ws.org/Vol-1327/icbo2014\\_paper\\_54.pdf](http://ceur-ws.org/Vol-1327/icbo2014_paper_54.pdf)
- ACTION: FRANK: would like to take use cases, go through to see what is modeled in ICO supports use cases. So:
  - REVIEW all 4 use cases and define them clearly as we did in #1.
  - NEXT MEETING:
    - define 2nd use case.
    - identify Frank's ontology team.
- NOT DISCUSSED ON 3/3 (tabled)
  - Terms relevant to biobanking that require def:  
<https://github.com/ICO-ontology/ICO/issues>
  - Inclusion of d-acts terms in ICO.
  - What are the core terms defined in ICO and how related to d-acts
  - Can use biobank consent from our repository as an example to test the core terms in the ICO. In addition, general informed consent terms needed by biobank will be added in the ICO and biobank specific consent terms will be added in OBIB
  - Track in github.
  - Can review ontology in ontobee (<http://www.ontobee.org/ontology/ICO> vs. protege.):
    - jie updated ICO on webProtege:
    - <http://webprotege.stanford.edu/#Edit:projectId=2dc11696-19bf-4412-b59d-17d205dd25fe>
- Housekeeping:
  - switching to webex. TBA
  - meeting frequency: keep at 2 weeks but skip next one.
  - next meeting: 3/31

=====OLD NOTES=====

## AGENDA

Date 2/4/16

### Attendees:

Chris Stoeckert  
 Heather Williams  
 Jihad Obeid  
 Mathias Brochhausen  
 Helena Ellis  
 Jie Zheng

### Not today:

Frank Manion

### Notes:

- Congrats on U01 submission
  - Review in May/Score
  - Council in August

- Specified start date: 9/1/16
- review terms in ICO [POSTPONE TILL NEXT VISIT]
- So for NEXT MEETING:
  - especially those relevant to biobanking that require def: <https://github.com/ICO-ontology/ICO/issues>
  - review current ICO
  - review gaps (e.g. what we said in the grant)
  - + what we have in d-acts (need inclusion from d-acts) in close collaboration with U Mich.
  - Can use biobank consent from (OBIB) as an example to test the core terms in the ICO
  - What are the core terms defined in ICO and how related to d-acts
  - Will want to capture terms and changes will want to track in github.
  - Can review ontology in ontobee (vs. protege.):
    - jie updated ICO on webProtege:
    - <http://webprotege.stanford.edu/#Edit:projectId=2dc11696-19bf-4412-b59d-17d205dd25fe>
- Biobank Consent Ontol calls: continue on same schedule?
  - Do we have a name as an affinity group or working group?: working group
    - Current focus: have to keep focus on ICO for biobanking.
  - Do we invite others? (e.g. from ECAG?)
    - as long the focus remains on Biobanking consent.